These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 23529848)
1. The patient journey in chronic myeloid leukemia patients on tyrosine kinase inhibitor therapies: qualitative insights using a global ethnographic approach. Guilhot F; Coombs J; Szczudlo T; Zernovak O; Paolantonio M; Bender C; Macdonald NJ; Shapiro A Patient; 2013; 6(2):81-92. PubMed ID: 23529848 [TBL] [Abstract][Full Text] [Related]
2. Which health-related quality of life aspects are important to patients with chronic myeloid leukemia receiving targeted therapies and to health care professionals? GIMEMA and EORTC Quality of Life Group. Efficace F; Breccia M; Saussele S; Kossak-Roth U; Cardoni A; Caocci G; Chie W; Naeem A; Nicolatou-Galitis O; Cocks K; Vignetti M; Baccarani M; Mandelli F; Sprangers M Ann Hematol; 2012 Sep; 91(9):1371-81. PubMed ID: 22543826 [TBL] [Abstract][Full Text] [Related]
3. Use of tyrosine kinase inhibitors for chronic myeloid leukemia: management of patients and practical applications for pharmacy practitioners. Wong SF; Mirshahidi H Ann Pharmacother; 2011 Jun; 45(6):787-97. PubMed ID: 21672900 [TBL] [Abstract][Full Text] [Related]
4. Patients' and hematologists' concerns regarding tyrosine kinase-inhibitor therapy in chronic myeloid leukemia. Jiang Q; Yu L; Gale RP J Cancer Res Clin Oncol; 2018 Apr; 144(4):735-741. PubMed ID: 29380058 [TBL] [Abstract][Full Text] [Related]
5. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia. Steinberg M Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072 [TBL] [Abstract][Full Text] [Related]
6. Experiences of living with chronic myeloid leukaemia and adhering to tyrosine kinase inhibitors: A thematic synthesis of qualitative studies. Hewison A; Atkin K; McCaughan D; Roman E; Smith A; Smith G; Howell D Eur J Oncol Nurs; 2020 Apr; 45():101730. PubMed ID: 32169687 [TBL] [Abstract][Full Text] [Related]
7. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients. Jain P; Kantarjian HM; Ghorab A; Sasaki K; Jabbour EJ; Nogueras Gonzalez G; Kanagal-Shamanna R; Issa GC; Garcia-Manero G; Kc D; Dellasala S; Pierce S; Konopleva M; Wierda WG; Verstovsek S; Daver NG; Kadia TM; Borthakur G; O'Brien S; Estrov Z; Ravandi F; Cortes JE Cancer; 2017 Nov; 123(22):4391-4402. PubMed ID: 28743165 [TBL] [Abstract][Full Text] [Related]
8. Clinical Features and Treatment Outcomes of 51 Patients with Chronic Myeloid Leukemia Treated with a Tyrosine Kinase Inhibitor at a Single Institution from 2002 to 2014. Kawano N; Yoshida S; Kawano S; Kuriyama T; Yamashita K; Ochiai H; Shimoda K; Ishikawa F; Ueda A; Kikuchi I J Clin Exp Hematop; 2016; 56(1):34-42. PubMed ID: 27334856 [TBL] [Abstract][Full Text] [Related]
9. Current perspectives for the treatment of chronic myeloid leukemia. Aladağ E; Haznedaroğlu İC Turk J Med Sci; 2019 Feb; 49(1):1-10. PubMed ID: 30761815 [TBL] [Abstract][Full Text] [Related]
10. Chronic myeloid leukemia (CML): association of treatment satisfaction, negative medication experience and treatment restrictions with health outcomes, from the patient's perspective. Hirji I; Gupta S; Goren A; Chirovsky DR; Moadel AB; Olavarria E; Victor TW; Davis CC Health Qual Life Outcomes; 2013 Oct; 11():167. PubMed ID: 24099272 [TBL] [Abstract][Full Text] [Related]
11. Variables associated with patient-reported outcomes in persons with chronic myeloid leukemia receiving tyrosine kinase-inhibitor therapy. Jiang Q; Wang HB; Yu L; Gale RP J Cancer Res Clin Oncol; 2017 Jun; 143(6):1013-1022. PubMed ID: 28251350 [TBL] [Abstract][Full Text] [Related]
12. Exploring Patient Decision Making Regarding Discontinuation of Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia. Flynn KE; Myers JM; D'Souza A; Schiffer CA; Thompson JE; Atallah E Oncologist; 2019 Sep; 24(9):1253-1258. PubMed ID: 30944185 [TBL] [Abstract][Full Text] [Related]
13. Factors Associated With Tyrosine Kinase Inhibitor Initiation and Adherence Among Medicare Beneficiaries With Chronic Myeloid Leukemia. Winn AN; Keating NL; Dusetzina SB J Clin Oncol; 2016 Dec; 34(36):4323-4328. PubMed ID: 27998234 [TBL] [Abstract][Full Text] [Related]
14. Molecular monitoring of tyrosine kinase inhibitor therapy of chronic myeloid leukemia in China. Jiang Q; Gale RP J Cancer Res Clin Oncol; 2016 Jul; 142(7):1549-55. PubMed ID: 27085530 [TBL] [Abstract][Full Text] [Related]
15. Adherence to tyrosine kinase inhibitors among Medicare Part D beneficiaries with chronic myeloid leukemia. Shen C; Zhao B; Liu L; Shih YT Cancer; 2018 Jan; 124(2):364-373. PubMed ID: 28976559 [TBL] [Abstract][Full Text] [Related]
16. Incidence of second malignancies during treatment of chronic myeloid leukemia with tyrosine kinase inhibitors in the Czech Republic and Slovakia. Voglova J; Muzik J; Faber E; Zackova D; Klamova H; Steinerova K; Michalovicova Z; Demitrovicova L; Cmunt E; Novakova L; Tothova E; Belohlavkova P; Mayer J; Indrak K Neoplasma; 2011; 58(3):256-62. PubMed ID: 21395367 [TBL] [Abstract][Full Text] [Related]
17. Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring. Jabbour E; Kantarjian H Am J Hematol; 2020 Jun; 95(6):691-709. PubMed ID: 32239758 [TBL] [Abstract][Full Text] [Related]
18. Experiences and perspectives on the GIST patient journey. Macdonald N; Shapiro A; Bender C; Paolantonio M; Coombs J Patient Prefer Adherence; 2012; 6():253-62. PubMed ID: 22536061 [TBL] [Abstract][Full Text] [Related]
19. Health-related quality of life during bosutinib (SKI-606) therapy in patients with advanced chronic myeloid leukemia after imatinib failure. Whiteley J; Reisman A; Shapiro M; Cortes J; Cella D Curr Med Res Opin; 2016 Aug; 32(8):1325-34. PubMed ID: 27045164 [TBL] [Abstract][Full Text] [Related]
20. Effect of Adherence-enhancing Interventions on Adherence to Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukemia (TAKE-IT): A Quasi-experimental Pre-Post Intervention Multicenter Pilot Study. Leader A; Benyamini N; Gafter-Gvili A; Dreyer J; Calvarysky B; Amitai A; Yarchovsky-Dolberg O; Sharf G; Tousset E; Caspi O; Ellis M; Levi I; De Geest S; Raanani P Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):e449-e461. PubMed ID: 30030034 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]